NCT06847269View on ClinicalTrials.gov

CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia

PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

March 31, 2030

Study Completion Date

April 30, 2031

Conditions
Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic Leukemia
Interventions
DRUG

Fludarabine

Given IV

DRUG

Cyclophosphamide

Given IV

DRUG

Mesna

Given IV

BIOLOGICAL

CD19-CAR T cell Infusion

Patients will receive the CD19-CAR T cells by vein, through either an IV or a central line.

Trial Locations (1)

38105

RECRUITING

St. Jude Children's Research Hospital, Memphis

All Listed Sponsors
lead

St. Jude Children's Research Hospital

OTHER

NCT06847269 - CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia | Biotech Hunter | Biotech Hunter